At the Regional Cancer Center we believe that patients and physicians benefit from being involved in clinical trials. Clinical trials help advance the science of cancer care, including new approaches to diagnosis, treatment and support of cancer patients.
The Regional Cancer Center is a member of the Southeast Clinical Oncology Research Consortium (SCOR) Southeastclinicaloncology.org, bringing more than 150 National cancer Institute sponsored trials to our local community. In addition we partner with other organizations to participate in rese arch in specific areas.
Our team of cancer experts strives to make the cutting edge technology available across the world acessible right here in Southwest Flroida.
| ATHENA/Clovis Oncology | ATHENA (A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy) |
|---|---|
| PaTK02/Advantagene, Inc. | Neoadjuvant GMCITM Plus Chemoradiation For Advanced Non-metastatic Pancreatic Adenocarcinoma |
| FL pancreas Collaborative/ Moffit | The Florida Pancreas Collaborative Next-Generation Biobank: Reducing Health Disparities and Improving Survival for Pancreatic Cancer |
| Keynote-937/Merck 3475-937 | A Phase 3 Double-Blinded, Two-Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937) |
| CALLA/Astra Zeneca | A Phase III, Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With and following Chemoradiotherapy Compared to Chemradiotherapy alone for treatment in Women with locally advanced Cervical Cancer (CALLA) |
| Study ID | Study Title | Study ID | Study Title |
|---|---|---|---|
| BR003 | A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide BR003 Followed by Weekly Paclitaxel with or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer |
GI004 | Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy GI004 with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer |
| BR002 | A Phase IIR/111 Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or BROO2 GY006 Surgical Ablation for Newly Oligometastatic Breast Cancer |
GY006 | A Randomized phase II trial of radiation therapy and cisplatin alone or in combination with intravenous triapine in women with newly diagnosed bulky stage 1B2, or stage II, IIIB, or IVA cancer of the uterine cervix or stage II-1VA vaginal cancer. |
| GU006 | A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer |
CC004 | Phase II Double Blind Dose Finding Trial of Bupropion CC004 Versus Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer |
| A021502 | Randomized Trial of Standard Chemotherapy Aloneor Combined with Atezolizumab as Adjuvant Therapy for A021502 51613 Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair |
S1613 | A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) with HER-2 Amplification |